- By insider
Meridian Bioscience Inc (VIVO) files its latest 10-K with SEC for the fiscal year ended on September 30, 2018. Meridian Bioscience Inc is an integrated life science company. It is engaged in development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases. Meridian Bioscience Inc has a market cap of $789.401 million; its shares were traded at around $18.62 with a P/E ratio of 33.21 and P/S ratio of 3.80. The dividend yield of Meridian Bioscience Inc stocks is 2.69%. Meridian Bioscience Inc had annual average EBITDA growth of 2.00% over the past ten years.
For the last quarter Meridian Bioscience Inc reported a revenue of $53.1 million, compared with the revenue of $49.70 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $213.6 million, an increase of 6.4% from last year. For the last five years Meridian Bioscience Inc had an average revenue growth rate of 2.3% a year.
The reported diluted earnings per share was 56 cents for the year, an increase of 9.8% from previous year. Over the last five years Meridian Bioscience Inc had an average EPS decline of 10.8% a year. The Meridian Bioscience Inc had a decent operating margin of 20.9%, compared with the operating margin of 21.92% a year before. The 10-year historical median operating margin of Meridian Bioscience Inc is 28.66%. The profitability rank of the company is 7 (out of 10).
At the end of the fiscal year, Meridian Bioscience Inc has the cash and cash equivalents of $59.8 million, compared with $57.1 million in the previous year. The company had no long term debt, compared with $50.1 million in the previous year. Meridian Bioscience Inc has a financial strength rank of 8 (out of 10).
At the current stock price of $18.62, Meridian Bioscience Inc is traded at 19.5% discount to its historical median P/S valuation band of $23.14. The P/S ratio of the stock is 3.80, while the historical median P/S ratio is 4.70. The stock gained 31.41% during the past 12 months.
Directors and Officers Recent Trades:
For the complete 20-year historical financial data of VIVO, click here.
This article first appeared on GuruFocus.